SCHEMBL320158

SCHEMBL320158

COc1ccc(C(F)(F)F)cc1-c1ccnnc1C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 3/20 0.42
PDE10A Q9Y233 3/20 0.42
CYP1A2 P05177 1/20 0.38
METAP2 P50579 1/20 0.38
RAB9A P51151 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CETP P11597 2/20 0.37
PDE6D O43924 1/20 0.37
PDE6A P16499 1/20 0.37
PDE6G P18545 1/20 0.37
PDE6B P35913 1/20 0.37
PDE6C P51160 1/20 0.37
PDE6H Q13956 1/20 0.37
GPBAR1 Q8TDU6 1/20 0.37
TP53 P04637 1/20 0.37
ALPL P05186 1/20 0.37
CRHR1 P34998 1/20 0.37
CTSA P10619 2/20 0.36
PTGDR2 Q9Y5Y4 2/20 0.36
TNIK Q9UKE5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL319508 0.79 TOP2A (0.44) PDE2APDE10ACYP1A2
SCHEMBL320538 0.79 PDE2A (0.41) PDE2APDE10ARAB9AL3MBTL1CETP
SCHEMBL1104997 0.75 SCN9A (0.48) CTSAPTGDR2TNIKSCN9A
SCHEMBL5991709 0.73 KIF11 (0.52) CYP1A2METAP2CTSAPTGDR2TNIK
SCHEMBL24072859 0.71 CTSA (0.49) RAB9ACTSA
SCHEMBL10147885 0.71 NOTUM (0.43) PDE2APDE10ACYP1A2METAP2L3MBTL1
SCHEMBL17214862 0.71 MAPT (0.47) PDE2APDE10ACYP1A2RAB9AL3MBTL1
SCHEMBL169247 0.70 GAA (0.55) RAB9AL3MBTL1ALPL
SCHEMBL5988812 0.70 KMT2A (0.51) PDE2APDE10ARAB9AL3MBTL1TP53
SCHEMBL3641254 0.69 PTGDR2 (0.60) CTSAPTGDR2CASR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
US-9145407-B2 Sulfonamide compounds PFIZER LIMITED (GB) 2015-09-29 US disclosed
EP-2590972-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2015-01-21 EP disclosed
EP-2590972-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2015-01-21 EP disclosed
EP-2590972-A2 CHEMICAL COMPOUNDS Pfizer Limited (GB) 2013-05-15 EP disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
US-20130109667-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012004706-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109667-A1 Chemical Compounds SCN1A, SCN7A, SCN1B PDE2A 1508/4885PDE10A 430/4885CYP1A2 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.